HS022

Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3 active Small molecule

HS022 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.

At a glance

Generic name	HS022
Sponsor	Zhejiang Hisun Pharmaceutical Co. Ltd.
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

While the exact molecular target of HS022 has not been widely disclosed in public literature, it is being developed by Zhejiang Hisun Pharmaceutical as an oncology agent in Phase 3 clinical trials. The drug likely works through inhibition of a key signaling pathway implicated in tumor growth, though specific mechanistic details remain proprietary.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HS022 CI brief — competitive landscape report
HS022 updates RSS · CI watch RSS
Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI